Reply to: “Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients”

Yael Renert-Yuval; Emma Guttman-Yassky

doi:10.1111/all.15285

Reply to: “Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients”

Yael Renert-Yuval
, Emma Guttman-Yassky^*

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	2269-2270
Number of pages	2
Journal	Allergy: European Journal of Allergy and Clinical Immunology
Volume	77
Issue number	7
DOIs	https://doi.org/10.1111/all.15285
State	Published - Jul 2022
Externally published	Yes

Funding

Funders	Funder number
AntibioTx
Kiniksa Pharma
Union Therapeutics
Boehringer Ingelheim
AMGEN
Janssen Biotech
National Center for Advancing Translational Sciences	UL1TR001866
AbbVie
Allergan
Asana Biosciences

Access to Document

10.1111/all.15285

Cite this

@article{e7877cc999ed4b8aae58673b3631ebaf,

title = "Reply to: “Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients”",

author = "Yael Renert-Yuval and Emma Guttman-Yassky",

year = "2022",

month = jul,

doi = "10.1111/all.15285",

language = "אנגלית",

volume = "77",

pages = "2269--2270",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "7",

}

TY - JOUR

T1 - Reply to

T2 - “Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients”

AU - Renert-Yuval, Yael

AU - Guttman-Yassky, Emma

PY - 2022/7

Y1 - 2022/7

UR - https://www.scopus.com/pages/publications/85133067656

U2 - 10.1111/all.15285

DO - 10.1111/all.15285

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 35770817

AN - SCOPUS:85133067656

SN - 0105-4538

VL - 77

SP - 2269

EP - 2270

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 7

ER -

Reply to: “Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients”

Funding

Access to Document

Other files and links

Cite this